Physician profile
Gabriel Mendoza
NPI 1437619871
$15,620.03
in general payments reported to CMS, 2019-2025
12 companies · $8,333 in 2025
The $8,333 reported for 2025 was more than what 89% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $508 · 2023: $2,247 · 2024: $4,531 · 2025: $8,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $2,277 · Consulting Fee: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,455.66 |
| Food and Beverage | $2,276.51 |
| Consulting Fee | $379.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,533.80 | 2023-2025 | Arexvy |
| Biocryst US Sales Co., LLC | $557.14 | 2022-2024 | Orladeyo |
| Astrazeneca Pharmaceuticals Lp | $554.58 | 2022-2024 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $470.86 | 2023-2024 | |
| Adma Biomanufacturing LLC | $379.43 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $336.00 | 2022-2023 | Takhzyro |
| Blueprint Medicines Corporation | $272.76 | 2022-2024 | Ayvakit |
| Amgen INC. | $204.22 | 2022-2023 | Tezspire |
| Alk-Abello, INC | $161.21 | 2023 | Grastek, Ragwitek, Odactra |
| Csl Behring | $85.65 | 2023 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $38.66 | 2024 | Dupixent |
| Genentech, INC. | $25.72 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.